Active substance
Results for the substance caplacizumab
1 result
About this active substance
Caplacizumab is a medication used for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a rare but serious condition characterized by the formation of blood clots in small vessels. It is a monoclonal antibody that targets von Willebrand factor, preventing its interaction with platelets.
By inhibiting von Willebrand factor activity, caplacizumab helps reduce clot formation and prevent severe complications such as organ failure. It is used in combination with plasma exchange and other standard treatments for aTTP.
The medication is administered as a subcutaneous injection, usually daily, for the duration of treatment. Patients need to be closely monitored to assess the therapy's effectiveness and detect potential side effects.
Side effects may include bleeding, injection site reactions, headaches, and fatigue. It is important for patients to inform their doctor of any unusual symptoms or adverse reactions.
By inhibiting von Willebrand factor activity, caplacizumab helps reduce clot formation and prevent severe complications such as organ failure. It is used in combination with plasma exchange and other standard treatments for aTTP.
The medication is administered as a subcutaneous injection, usually daily, for the duration of treatment. Patients need to be closely monitored to assess the therapy's effectiveness and detect potential side effects.
Side effects may include bleeding, injection site reactions, headaches, and fatigue. It is important for patients to inform their doctor of any unusual symptoms or adverse reactions.